Characteristic | No. of patients (%) | 1-year OS rated (%) | P value |
---|---|---|---|
Sex | Â | Â | 0.006 |
 Men | 37 (92.5) | 67.6 |  |
 Women | 3 (7.5) | 0.0 |  |
Agea (years) | 58 (41–80) |  |  |
ECOG performance status | Â | Â | 0.267 |
 0–1 | 11 (27.5) | 68.2 |  |
 2 | 29 (72.5) | 55.2 |  |
Primary tumor location | Â | Â | 0.403 |
 Upper | 12 (30.0) | 50.0 |  |
 Middle | 26 (65.0) | 65.4 |  |
 Lower | 2 (5.0) | 100.0 |  |
T category of primary tumorb | Â | Â | 0.392 |
 T1 | 2 (5.0) | 100.0 |  |
 T2 | 3 (7.5) | 100.0 |  |
 T3 | 21 (52.5) | 57.1 |  |
 T4 | 14 (35.0) | 57.1 |  |
Clinical stage of primary tumorb | Â | Â | 0.526 |
 IIA–IIB | 2 (5.0) | 100 |  |
 IIIA–IIIC | 29 (72.5) | 62.1 |  |
 IV | 9 (22.5) | 55.5 |  |
NRS score of 3–4c | |||
 Before nutrition support | 22 (55.0) | –e |  |
 After nutrition support | 6 (15.0) | – |  |
Hemoglobin level after CCRTa (g/L) | 110 (56–156) | – |  |
Total energy intakea (kcal/day) | 2166 (1956–2213) | – |  |
Total protein intakea (g/kg per day) | 1.53 (1.41–1.76) | – |  |
Fistula closure | 32 (80.0) | – |  |
Time to fistula closurea (weeks) | 5 (2–11) | – |  |
Fistula site | Â | Â | 0.435 |
 Trachea and bronchus | 7 (17.5) | 57.1 |  |
 Mediastinum | 33 (82.5) | 63.6 |  |
Radiation dosea (Gy) | 60 (46–68) |  | <0.001 |
 <60 | 14 (35.0) | 50.0 |  |
 ≥60 | 26 (65.0) | 69.2 |  |
Concurrent chemotherapy | Â | Â | 0.333 |
 DDP + 5-FU | 7 (17.5) | 42.9 |  |
 Docetaxel-based regimens | 33 (82.5) | 66.7 |  |
Clinical tumor response after CCRT | Â | Â | <0.001 |
 CR | 12 (30.0) | 91.7 |  |
 PR | 20 (50.0) | 65.0 |  |
 SD | 3 (7.5) | 33.3 |  |
 PD | 5 (12.5) | 0 |  |